Clinical trial · Observational
Head and Neck Cancer Registry (LORHAN)
Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy Other Than Surgical Resection Alone for Newly Diagnosed Head and Neck Cancer
NCT01080313CI-TRIAL-00006247LORHANcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this study is to describe, in detail, patterns of care for head and neck carcinoma patient
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Therapy for head and neck cancer | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with head and neck cancer
- interventionNames
- Other: Therapy for head and neck cancer
Primary outcomes (1)
- measure
- Patterns of care for head and neck cancer
- timeFrame
- up to 10 years
Secondary outcomes (4)
- measure
- Overall survival by treatment regimen
- timeFrame
- study entry to death from any cause or to end of study
- measure
- Determine the incidence and severity of major dose-limiting and other important treatment toxicities
- timeFrame
- up to 10 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically (histologically or cytologically) confirmed new diagnosis of carcinoma involving the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or neck node metastasis from unknown origin * Scheduled to receive radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy * Written informed consent Exclusion Criteria: * Registry participation does not exclude participation in clinical trials. * Patients scheduled to receive or who have received surgery are eligible for Registry participation as long as they are also scheduled to receive medical therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.